Table 2.
Univariate analysis for PFS and OS.
| Variables | Subgroups | PFS | OS | ||
|---|---|---|---|---|---|
| Median (ms) | p | Median (ms) | p | ||
| MGMT status | 0.05 | 0.02 | |||
| Met | 2.3 | 11.7 | |||
| Unmet | 2.004 | 6.5 | |||
| ECOG PS | 0–1 | 2.1 | 0.5 | 9.3 | 0.1 |
| 2 | 2.1 | 7.09 | |||
| Line of Depatux-M treatment | 0.14 | 0.3 | |||
| 2nd line | 2.3 | 9.4 | |||
| >2nd line | 2.04 | 7.1 | |||
| Start of Depatux-M since TMZ | 0.14 | 0.45 | |||
| ≤16 wks | 4.6 | 9.1 | |||
| >16 wks | 2.1 | 8.04 | |||
ECOG PS: Eastern Cooperative Oncology Group Performance Status; MGMT: O-6-methylguanine-DNA methyltransferase; TMZ: temozolomide; PFS: progression-free survival; OS: overall survival; the statistically significant variables are in bold.